Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rap1 siRNA is a small interfering RNA molecule designed to silence the expression of Rap1, a member of the Ras family of small GTPases. In the context of oncology research, particularly glioblastoma, Rap1 siRNA is used to investigate the role of Rap1 in thrombin-induced cell proliferation, adhesion, and ERK1/2 signaling. By down-regulating Rap1 expression, researchers have demonstrated its critical involvement in G-protein-coupled receptor (GPCR) mediated pathways and tumor growth. While primarily used as a research tool to study intracellular signaling and inside-out integrin activation, it represents a potential therapeutic approach for inhibiting pathways that drive malignancy in brain tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rap1 siRNA.